ストックスクリーナーアプリを入手
5.50
3.38%
0.18
プレマーケット:
5.35
-0.15
-2.73%
前日終値:
$5.32
開ける：
$5.32
24時間の取引高:
12.69M
Relative Volume:
0.53
時価総額：
$2.21B
収益：
$64.60M
当期純損益:
$-377.75M
株価収益率:
-3.5484
EPS:
-1.55
ネットキャッシュフロー:
$-335.64M
1週間 パフォーマンス:
+21.95%
1か月 パフォーマンス:
-19.59%
6か月 パフォーマンス:
-16.03%
1年 パフォーマンス:
-26.37%
1日の値動き範囲:
$5.235
$5.535
1週間の範囲:
$4.86
$6.00
52週間の値動き範囲:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
名前
Recursion Pharmaceuticals Inc
セクター
電話
(385) 269-0203
住所
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.50 | 2.21B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-22 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 開始されました | Needham | Buy |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-04 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 開始されました | Berenberg | Buy |
| 2021-05-11 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Goldman | Neutral |
| 2021-05-11 | 開始されました | JP Morgan | Neutral |
| 2021-05-11 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal - Yahoo Finance
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy? - Yahoo Finance
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - MSN
Recursion Pharmaceuticals Licenses HealthVerity's Real-World Data - marketscreener.com
Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data - MarketScreener
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data - MarketScreener
Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA” - MSN
Tech Firms Dominate Monday’s 10 Worst Performers - Insider Monkey
Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday? - MSN
Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks - Insider Monkey
Why Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday? - MSN
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? - Benzinga
Why Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week? - MSN
Recursion Pharma (RXRX) Stock Climbs Amid FDA Shift In Testing R - GuruFocus
10 Firms Defy Market Slump, Record Double-Digit Gains Last Week - Insider Monkey
Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks - Insider Monkey
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today - MSN
Biotech Revolution: FDA’s New Era Signals Dramatic Shift in Drug Development - macnifico.pt
This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now? - The Globe and Mail
Recursion Pharma rises, Intel & Five Below fall: Trending Tickers - Yahoo Finance
Recursion: FDA To Replace Animal Testing With AI?A Small But Necessary Win - Seeking Alpha
Recursion (RXRX) Utilizes AI for Enhanced Drug Discovery - GuruFocus
The AI Revolution in Biotech: Recursion Pharmaceuticals Soars 19.18% on FDA's New Approach to Animal Testing - RagingBull
Recursion Pharmaceuticals Shares Are Up Today: what's Going On? - Benzinga
Nvidia-Backed Recursion Pharma Soars After-Hours As FDA Eyes AI Over Animal Testing For Drugs: Retail Traders Elated - MSN
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study - Zacks Investment Research
Recursion Pharmaceuticals, Enamine release new tools in its AI/ML platform - TipRanks
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries - The Manila Times
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March - MSN
Recursion Pharmaceuticals Strengthens Board with New Appointments - MSN
Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment - marketscreener.com
Recursion begins phase 1 study of lymphoma treatment - Investing.com
Strategic Positioning and Operational Resilience Justify Buy Rating for Recursion Pharmaceuticals - TipRanks
Recursion Pharmaceuticals (NasdaqGS:RXRX) Sees 27% Weekly Drop After Leadership Changes - Yahoo Finance
Long Term Trading Analysis for (RXRX) - news.stocktradersdaily.com
Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market - Yahoo Finance
Recursion to Participate in Upcoming Investor Conference - Bluefield Daily Telegraph
Recursion stock hits 52-week low at $5.5 amid market challenges - Investing.com Canada
Recursion stock hits 52-week low at $5.5 amid market challenges By Investing.com - Investing.com South Africa
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today - Yahoo Finance
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks? - Yahoo
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks - The Motley Fool
Recursion Pharmaceuticals Inc (RXRX) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):